Sarah L Grimshaw, Rachel Conyers, Elvira C van Dalen, Kirsten Ness, Emma J Verwaaijen
{"title":"Establishing consensus on defining the physically vulnerable child with cancer: a protocol for an international Delphi approach.","authors":"Sarah L Grimshaw, Rachel Conyers, Elvira C van Dalen, Kirsten Ness, Emma J Verwaaijen","doi":"10.1136/bmjpo-2025-003401","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Childhood cancer survivors have an increased risk of lifetime morbidity and mortality. To improve outcomes, the physical impact of treatment toxicity must be minimised in the acute phase. Using a framework to identify early signs of physical vulnerability could provide an avenue for early intervention. Yet, existing models of physical vulnerability (sarcopenia and frailty) are adult-based definitions and require adaptation as they do not reflect the unique pathophysiology of paediatric cancer. Using phenotypes of sarcopenia and frailty as base, this study aims to establish a consensus definition of the physically vulnerable child with cancer.</p><p><strong>Methods and analysis: </strong>A Delphi consensus approach is guided by a project team of four specialised oncology healthcare professionals. Five stages include defining the problem area, selecting panel members, conducting four Delphi rounds, establishing closing criteria and validation of results. A focus group of international experts will meet to define the problem area, in addition to a scoping review to collate existing definitions and assessments of sarcopenia and frailty within paediatric contexts. Delphi panel members will include multinational clinicians with >5 years' experience in the acute paediatric setting, and researchers specialising in sarcopenia and/or frailty in paediatric cancer. Delphi rounds will aim to achieve consensus on how to define physical vulnerability in children with cancer. Consensus will be considered achieved when 80% or more of panellists agree. A series of focus groups with select members of the Delphi panel, and families, children, and adolescents affected by paediatric cancer will be held to validate results.</p><p><strong>Ethics and dissemination: </strong>The study has ethics approval through the Royal Children's Hospital Human Ethics Committee (number 3707). Results from this study will be published in peer-reviewed academic journals and disseminated via scientific conference(s) and key stakeholders.</p>","PeriodicalId":9069,"journal":{"name":"BMJ Paediatrics Open","volume":"9 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182134/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Paediatrics Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjpo-2025-003401","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Childhood cancer survivors have an increased risk of lifetime morbidity and mortality. To improve outcomes, the physical impact of treatment toxicity must be minimised in the acute phase. Using a framework to identify early signs of physical vulnerability could provide an avenue for early intervention. Yet, existing models of physical vulnerability (sarcopenia and frailty) are adult-based definitions and require adaptation as they do not reflect the unique pathophysiology of paediatric cancer. Using phenotypes of sarcopenia and frailty as base, this study aims to establish a consensus definition of the physically vulnerable child with cancer.
Methods and analysis: A Delphi consensus approach is guided by a project team of four specialised oncology healthcare professionals. Five stages include defining the problem area, selecting panel members, conducting four Delphi rounds, establishing closing criteria and validation of results. A focus group of international experts will meet to define the problem area, in addition to a scoping review to collate existing definitions and assessments of sarcopenia and frailty within paediatric contexts. Delphi panel members will include multinational clinicians with >5 years' experience in the acute paediatric setting, and researchers specialising in sarcopenia and/or frailty in paediatric cancer. Delphi rounds will aim to achieve consensus on how to define physical vulnerability in children with cancer. Consensus will be considered achieved when 80% or more of panellists agree. A series of focus groups with select members of the Delphi panel, and families, children, and adolescents affected by paediatric cancer will be held to validate results.
Ethics and dissemination: The study has ethics approval through the Royal Children's Hospital Human Ethics Committee (number 3707). Results from this study will be published in peer-reviewed academic journals and disseminated via scientific conference(s) and key stakeholders.